Cardiac allograft vasculopathy (CAV) is one of themajor late causes of mortality in cardiac transplant recipients beyond thefirst year. Given the lack of longer term data for PCI in cardiac transplantrecipients, we report ten year follow up of such cardiac transplant recipientswho underwent PCI at Mayo Clinic.

A retrospective observational study was conductedthat included cardiac transplant recipients who underwent PCI at the MayoClinic. Continuous variables were presented as mean (SD) or median (IQR) anddiscrete variables were presented as frequency (percentage). 

Thirty-eight consecutive cardiac transplant recipientsunderwent PCI from January 1, 1995, to June 30, 2023, at the Mayo Clinic. Themedian age of the cohort was 61.00 years (IQR:51.00-70.00) comprised predominantlyof men (65.80%), and 47.40% of the cohort presented with an acute coronarysyndrome. The antirejection therapy prior to the PCI included steroids (47.30%),cyclosporine (26.30%), tacrolimus (15.80%), mycophenolate (42.10%),azathioprine (13.10%), & sirolimus (31.57%).  Intravascular ultrasound during PCI wasutilized in 10.50% of the cases. The median time duration between hearttransplant and PCI was 9.00 years (IQR:6.00-13.00 years). Two individualsneeded repeat heart transplant for severe CAV. In hospital mortality was 5.20%and the long-term median survival was 7.20 years with a 10-year mortality rateof 65.70%.

This is the first publication reporting ten-yearoutcomes for PCI in cardiac transplant patients. The salient features for ourcohort were a 65.70% mortality rate at 10 years and a median survival of 7.20years.